Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health

Affiliations

¹ Department of Dermatology-Center of Pediatric Dermatology, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Center of Rare Skin Diseases, Vascular Anomaly Center Erasmus MC Rotterdam, the Netherlands.
² Department of Pediatrics (Hemato-oncology), Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Center of Rare Skin Diseases, Vascular Anomaly Center Erasmus MC Rotterdam, the Netherlands.
³ Department of Pediatric Cardiology, Wilhelmina Children's Hospital, University Medical Center Utrecht, the Netherlands.
⁴ Department of Dermatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, UMC Utrecht Center for Vascular Anomalies, the Netherlands.
⁵ Department of Intensive Care and Pediatric Surgery, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Center of Rare Skin Diseases, Vascular Anomaly Center Erasmus MC Rotterdam, the Netherlands.
⁶ Department of Surgery, Wilhelmina Children's Hospital, University Medical Center Utrecht, the Netherlands.
⁷ Department of Child and Adolescent Psychology/Psychiatry, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, the Netherlands.
⁸ Department of Plastic Surgery, Wilhelmina Children's Hospital, University Medical Center Utrecht, UMC Utrecht Center for Vascular Anomalies, the Netherlands.
⁹ Department of Plastic, Reconstructive and Hand Surgery, Amsterdam UMC Location University of Amsterdam, the Netherlands.
¹⁰ Department of Pharmacology and Toxicology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
¹¹ Department Emma Children's Hospital, Amsterdam UMC Location University of Amsterdam, the Netherlands.

PMID: 37128266
PMCID: PMC10148149
DOI: 10.1016/j.jdin.2023.02.001

Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health

Mireille M Hermans et al. JAAD Int. 2023.

. 2023 Feb 18:11:137-139.

doi: 10.1016/j.jdin.2023.02.001. eCollection 2023 Jun.

Authors

Affiliations

¹ Department of Dermatology-Center of Pediatric Dermatology, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Center of Rare Skin Diseases, Vascular Anomaly Center Erasmus MC Rotterdam, the Netherlands.
² Department of Pediatrics (Hemato-oncology), Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Center of Rare Skin Diseases, Vascular Anomaly Center Erasmus MC Rotterdam, the Netherlands.
³ Department of Pediatric Cardiology, Wilhelmina Children's Hospital, University Medical Center Utrecht, the Netherlands.
⁴ Department of Dermatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, UMC Utrecht Center for Vascular Anomalies, the Netherlands.
⁵ Department of Intensive Care and Pediatric Surgery, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Center of Rare Skin Diseases, Vascular Anomaly Center Erasmus MC Rotterdam, the Netherlands.
⁶ Department of Surgery, Wilhelmina Children's Hospital, University Medical Center Utrecht, the Netherlands.
⁷ Department of Child and Adolescent Psychology/Psychiatry, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, the Netherlands.
⁸ Department of Plastic Surgery, Wilhelmina Children's Hospital, University Medical Center Utrecht, UMC Utrecht Center for Vascular Anomalies, the Netherlands.
⁹ Department of Plastic, Reconstructive and Hand Surgery, Amsterdam UMC Location University of Amsterdam, the Netherlands.
¹⁰ Department of Pharmacology and Toxicology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
¹¹ Department Emma Children's Hospital, Amsterdam UMC Location University of Amsterdam, the Netherlands.

PMID: 37128266
PMCID: PMC10148149
DOI: 10.1016/j.jdin.2023.02.001

No abstract available

Keywords: adrenergic beta-antagonists; blood pressure; capillary hemangioma; child; growth and development; infant; long-term adverse effects; vascular malformations; vascular tissue neoplasms.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

References

1. Hermans M.M., Rietman A.B., Schappin R., et al. Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. Eur J Pediatr. 2023;182(2):757–767. - PMC - PubMed
1. Neuhauser H.K., Thamm M., Ellert U., Hense H.W., Rosario A.S. Blood pressure percentiles by age and height from nonoverweight children and adolescents in Germany. Pediatrics. 2011;127:e978–e988. - PubMed
1. Fredriks A.M., van Buuren S., Burgmeijer R.J.F., et al. Continuing positive secular growth change in the Netherlands 1955-1997. Pediatr Res. 2000;47:316–323. - PubMed
1. Raphael M.F., Breugem C.C., Vlasveld F.A., et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas? A cohort study. J Am Acad Dermatol. 2015;72:465–472. - PubMed
1. Sasaki M., North P.E., Elsey J., et al. Propranolol exhibits activity against hemangiomas independent of beta blockade. NPJ Precis Oncol. 2019;3:27. - PMC - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health

Affiliations

Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health

Authors

Affiliations

Conflict of interest statement

References

LinkOut - more resources

Full Text Sources